- Health Canada has approved Puma Biotechnology Inc's PBYI Nerlynx (neratinib) in combination with capecitabine for metastatic HER2-overexpressed/amplified breast cancer, who have received two or more prior anti-HER2-based regimens in the metastatic setting.
- Knight Therapeutics Inc KHTRF has the exclusive right to commercialize Nerlynx in Canada.
- Nerlynx is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the human epidermal growth factor receptors, HER1, HER2, and HER4.
- Price Action: PBYI shares are down 2.49% at $8.60 during the market session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
